Share
.webp)
.webp)
.webp)
.webp)
Kim McLean Boericke
Veristat, a global clinical research organization (CRO) and consultancy specializing in complex clinical studies, has appointed Kim McLean Boericke as Chief Executive Officer (CEO).
A seasoned executive with decades of leadership and operational experience in the clinical research industry, Boericke succeeds Patrick Flanagan.
After 13 years as CEO, Patrick Flanagan will transition to Veristat’s Board of Directors. During his tenure, Flanagan led the company through a period of sustained growth, significantly expanding its service offerings and supporting more than 180 regulatory application submissions worldwide. These efforts contributed to the approval of over 120 therapies, helping bring critical treatments to patients with unmet medical needs.
Boericke previously served as Veristat’s Chief Operating Officer and brings more than 25 years of experience across the life sciences and clinical research sectors. She has held senior leadership roles at Thread, ICON, IQVIA, i3 Research, and INC Research, where she played key roles in advising, planning, and delivering complex clinical development programs. She also serves as an active board member for MAPI Trust, including roles as Chairwoman and Independent Director. Boericke is among a small group of female executives leading global organizations in the life sciences industry.
As CEO, Boericke will focus on advancing Veristat’s evolution as a leader in data analytics, insights-driven clinical development, and global regulatory submissions. Her strategic priorities include expanding Veristat’s therapeutic expertise in oncology, neurology, and rare diseases, while strengthening the organization’s ability to support clients in efficiently advancing innovative therapies to patients worldwide.
